Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Financing Activities (2023 - 2025)

Kura Oncology (KURA) has disclosed Cash from Financing Activities for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 40.82% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 98.84% decrease, with the full-year FY2025 number at $1.8 million, down 98.84% from a year prior.
  • Cash from Financing Activities was $1.1 million for Q4 2025 at Kura Oncology, up from $515000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $148.4 million in Q1 2024 to a low of $84000.0 in Q3 2023.
  • A 3-year average of $17.4 million and a median of $806000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 2521.43% in 2024, then crashed 99.9% in 2025.
  • Kura Oncology's Cash from Financing Activities stood at $691000.0 in 2023, then grew by 16.64% to $806000.0 in 2024, then surged by 40.82% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Cash from Financing Activities are $1.1 million (Q4 2025), $515000.0 (Q2 2025), and $143000.0 (Q1 2025).